Founded in 2012 by Prof. Maciej Banach. A group of 150 experts aimed to investigate issues in the field of nutrition, lipid disorders, hypertension & CVD risk.
It’s time for recognitions! @ExpertLipid is not just about science, but also about friendship and -as my dad uses to say- things done with a smile always turn out better. So proud of Arrigo’s award today! @afgcicero@atherosociety#CvPrev
Prof. Arman Postadzhiyan discusses the SNAPSHOT and REVEALED studies
REVEALED - Real world EVidencE of Arterial hypertension and Lipids Evaluation Dynamics
#ILEP#Lipidology#Hypertension#CVD@maciejbanach
When it comes to #CvPrev, no single strategy is enough. We need to work on multiple fronts: healthy diet, 🏃🏃♀️, BP and lipid control, 🚬 cessation, 💊 therapy, & patient adherence. Each of these elements contributes to risk red—but none of them, alone, can do the job @ExpertLipid
I am so glad and happy to inform you that since the May 1st, 2025 within the new Ministry of Health program #MyHealth we are introducing the first (to my best knowledge) worldwide #screening measurement of the lipoprotein(a) #LPA in individuals at the age of 20-40 years‼️
Few facts about the program:
✔️ It is free and facultative, thus we all need to focus to convince everybody (#education) to check their health status and, within different measurements, make Lp(a) analysis.
✔️ It is finally a real preventive program, with well-designed pathways, and after the baseline survey, and diagnostic measurements, everyone will receive the individual health plan‼️
✔️Why is Lp(a) measurement important and included in the program? Lp(a) is the 5th most prevalent CVD risk factor, and as many as >20% of adults may have elevated Lp(a) (>50 mg/dl) in Poland, what equals even 6 million patients.
✔️ Elevated Lp(a) is significantly associated with the risk of #MI (included the risk of #premature #ASCVD/MI), ischemic #stroke, #PAD, aortic valve stenosis and #heartfailure; this risk is independent on all other CVD risk factors.
✔️Thus, measuring Lp(a) at the age of 20-40 years of age, we might not only invest in our health as early as possible, but also #prevent the first CVD event in parents and siblings within the #cascade #screening.
✔️ All should have Lp(a) measured, and for most of those individuals (due to the fact the Lp(a) levels are genetically predisposed), one measurement is enough.
✔️ All those with elevated Lp(a) should have CVD risk reassessment and optimization of the therapy (eventually with PCSK9 targeted therapy application within B101 program or emergency access for therapy), waiting for the targeted drugs that should be available in 2026/2027.
So, check your Lp(a) to be aware of your CVD risk, especially it is free and available in Poland‼️ Invest in your health as early as possible‼️ @Lpa_Doc@TIMIStudyGroup
Great, great thanks to everyone who made this happen‼️👏👏 @Leszczyna@MZ_GOV_PL@aga_mastalerz
How much do we really know about lipoprotein(a)?
At #ILEP2025, we’ll discuss Lp(a) and #CVD risk, new recommendations for #elderly patients, and if effective hyper-Lp(a) management is possible in 2025.
🗓 June 5-6, 2025 📍Warsaw
🔗 https://t.co/k8yE9617rZ
#Lipidology#Biomarkers